Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 951 + Chemotherapy +/- Bevacizumab in Advanced NSCLC
NCT00508625Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2006
- Primary completion
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of dulanermin in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Jun 2006; status: completed.
02
Drugs
dulanermin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00508625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508625.